ANTONY, France & LENOIR, N.C.--(BUSINESS WIRE)--STALLERGENES S.A. (Euronext Paris), world leader in sublingual immunotherapy and GREER® Laboratories, Inc., a leader in allergy immunotherapy in the United States today announced the signing of an exclusive agreement for the United States commercialization rights to Oralair®, an investigational grass allergy immunotherapy tablet currently under review by the FDA. Oralair® is a grass pollen sublingual immunotherapy tablet that includes five grasses (sweet vernal grass, orchard grass, perennial rye grass, timothy grass, and Kentucky bluegrass) and is being investigated for the treatment of grass pollen-induced allergic rhinitis or conjunctivitis in adults and children aged 5 and older. Grass allergies are the most common seasonal allergy in the United States and most people are allergic to more than one type of grass. The 5 grasses included in Oralair® provide a wide range of grass allergy coverage in the United States. If approved, Oralair® would be a tablet that dissolves under the tongue and could be self-administered at home after receiving the first dose in a physician’s office.
Help employers find you! Check out all the jobs and post your resume.
